Healthcare firm OPKO's Q3 revenue falls

OPKO Health

29/10/2025 20:37

Overview

OPKO Q3 2025 total revenue declines to $151.7 mln from $173.6 mln in 2024

Operating income rises to $48.1 mln in Q3 2025, aided by asset sale gain

Net income for Q3 2025 stable at $21.6 mln, EPS remains $0.03

Outlook

Company did not provide specific financial guidance for future periods in its press release

Result Drivers

REGENERON COLLABORATION - OPKO entered a research collaboration with Regeneron Pharmaceuticals, potentially exceeding $1 bln in value, which could drive future revenue through milestone payments and royalties

ASSET SALE TO LABCORP - Sale of BioReference oncology assets to Labcorp for $225 mln contributed to operating income gain

COST REDUCTION - Lower clinical test volumes from asset sale and cost-reduction initiatives at BioReference reduced expenses

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue from Services
$95.20 mln
Q3 Net Income
$21.60 mln
Q3 Basic EPS
$0.03
Q3 Operating Income
$48.10 mln
Q3 Pretax Profit
$41.40 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy."

Wall Street's median 12-month price target for OPKO Health Inc is $3.00, about 52% above its October 28 closing price of $1.44

Press Release: ID:nGNX67ggkq

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)